MR
Michael Rape
Founder of Lyterian Therapeutics
San Francisco Bay Area
Overview
Michael Rape is a Professor and Head of the Division of Molecular Therapeutics at UC Berkeley, an Investigator at HHMI, and the Founder of Nurix Tx and Lyterian Tx. His career highlights include founding two successful biotech companies and leading groundbreaking research in molecular therapeutics at a prestigious academic institution.
Work Experience
Co-Founder
2022 - Current
Lyterian Therapeutics focused on developing new drugs for diseases by using natural mechanisms of protein regulation.
Member, Scientific Advisory Board
2022
Head, Division of Molecular Therapeutics
2022
Professor
2006
iPartner
2021
Investigator
2013
The Howard Hughes Medical Institute, a non-profit medical research organization, aims to advance biomedical research and science education.
Raised $1,000,000.00 from Salt Lake Community College.
Member, Scientific Advisory Board
2020
Co-founder and member, Scientific Advisory Board
2012
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Raised $545,900,000.00 from Redmile Group, Boxer Capital, The Column Group, Foresite Capital, Third Rock Ventures, EcoR1 Capital, Wellington Management and Bain Capital Life Sciences.